phrykt

Avalyn Pharma Inc. (AVLN): who owns it and who trades it

As of Nov 12, 2026, AVLN insiders reported 4 open-market sales worth $6.7M and 3 purchases worth $20M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Fmr Llc (10% owner), with $6.7M.

Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, AVLN insiders reported $20M of open-market purchases and $6.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$20M
3 trades, 3 people
Sales, 12 months
$6.7M
4 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 12, 2026

Purchases and sales by month

$20M$20MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026Fmr Llc10% ownerSale5,565$29.56$165KForm 4
Nov 10, 2026Fmr Llc10% ownerSale47,889$30.28$1.5MForm 4
Nov 9, 2026Fmr Llc10% ownerSale173,661$29.06$5MForm 4
Nov 9, 2026Fmr Llc10% ownerSale1,339$29.75$39.8KForm 4
May 1, 2026Novo Holdings A/S10% ownerPurchase555,555$18.00$10MForm 4
May 1, 2026Jill CarrollDirectorPurchase277,778$18.00$5MForm 4
May 1, 2026Simeon George +110% ownerPurchase277,777$18.00$5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Novo Holdings A/S10% owner$10M–May 1, 2026
Fmr Llc10% owner–$6.7MNov 10, 2026
Jill CarrollDirector$5M–May 1, 2026
Simeon George10% owner$5M–May 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AVLN short interest

Moderate short interest. 5.2% of AVLN shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went up 309%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.30M AVLN shares were sold short, 5.2% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 434,319 shares, buying them all back would take about 5.3 trading days (days to cover).

Shares short, % of all shares

5.19%Jun 15Oct 306.08%

Days to cover

5.3May 15Oct 3012.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.30M5.19%-2%434,3195.3
Oct 15, 20262.35M5.31%-6%355,2446.6
Sep 30, 20262.52M5.68%+20%295,2068.5
Sep 15, 20262.09M4.72%+8%218,9249.6
Aug 31, 20261.93M4.35%-7%170,14611.3
Aug 14, 20262.07M4.68%+3%189,67910.9
Jul 31, 20262.02M4.55%-8%215,7369.4
Jul 15, 20262.19M4.94%+1%389,9065.6
Jun 30, 20262.17M4.88%+65%704,2583.1
Jun 15, 20261.31M2.95%+46%236,6715.5
May 29, 2026896,139–+59%278,1293.2
May 15, 2026562,374––416,6291.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Avalyn Pharma company events

Avalyn Pharma filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 16, 2026.

  1. Sep 16, 2026LeadershipUpon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of Avalyn Pharma Inc., the Board appointed Robert Meyer, M.D. to the Board as a Class II director for an initial term expiring at the annual meeting of stockholders in 2028. Filing
  2. Aug 12, 2026ResultsReleased financial results. Filing
  3. Jul 1, 2026AgreementAvalyn Pharma Inc. entered into a First Amendment to the Sublease, which amends that certain Sublease Agreement with CRISPR Therapeutics, Inc., dated as of August 29, 2025, providing for the lease of approximately 8,774 rentable square feet in the building located at 105 West First Street, Boston… Filing
  4. Jun 17, 2026AnnouncementShared information with investors. Filing
  5. Jun 3, 2026ResultsReleased financial results. Filing
  6. May 1, 2026RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Questions about Avalyn Pharma Inc. (AVLN) stock

Are AVLN insiders buying or selling?

In the last 12 months, AVLN insiders reported 3 open-market purchases worth $20M and 4 sales worth $6.7M. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in AVLN?

As of Oct 30, 2026, 2.30M AVLN shares were sold short, 5.2% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 434,319 shares, buying them all back would take about 5.3 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.